Marco Investment Management LLC Sells 400 Shares of Thermo Fisher Scientific Inc. $TMO

Marco Investment Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the second quarter, HoldingsChannel.com reports. The firm owned 11,162 shares of the medical research company’s stock after selling 400 shares during the quarter. Marco Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $4,526,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the period. Allworth Financial LP increased its holdings in Thermo Fisher Scientific by 7.8% in the 1st quarter. Allworth Financial LP now owns 20,244 shares of the medical research company’s stock worth $10,073,000 after acquiring an additional 1,461 shares in the last quarter. Alps Advisors Inc. increased its stake in Thermo Fisher Scientific by 19.4% in the 1st quarter. Alps Advisors Inc. now owns 3,496 shares of the medical research company’s stock worth $1,740,000 after buying an additional 568 shares in the last quarter. Finally, Cerity Partners LLC raised its position in shares of Thermo Fisher Scientific by 40.4% during the first quarter. Cerity Partners LLC now owns 226,777 shares of the medical research company’s stock valued at $112,845,000 after buying an additional 65,262 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.2%

Shares of TMO opened at $572.72 on Friday. The firm has a market capitalization of $215.18 billion, a price-to-earnings ratio of 33.09, a PEG ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a 50-day moving average of $518.58 and a 200 day moving average of $462.39.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific announced that its board has authorized a stock buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TMO. Leerink Partners lifted their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president owned 21,152 shares of the company’s stock, valued at $12,144,420.80. This trade represents a 1.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,420 shares of company stock worth $19,980,884 over the last 90 days. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.